Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA2 | Q15349 | 13/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.32 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4145558 | 0.91 | SYK (0.40) | RPS6KA2RPS6KA3SYK | |
| SCHEMBL4143768 | 0.87 | SYK (0.32) | RPS6KA2RPS6KA3SYKTBXA2RGPBAR1 | |
| SCHEMBL4139604 | 0.86 | RPS6KA2 (0.34) | RPS6KA2RPS6KA3 | |
| SCHEMBL4146049 | 0.86 | TBXAS1 (0.42) | RPS6KA2RPS6KA3 | |
| SCHEMBL3092098 | 0.81 | SRD5A2 (0.36) | RPS6KA2RPS6KA3 | |
| SCHEMBL4144632 | 0.81 | RPS6KA2 (0.34) | RPS6KA2RPS6KA3TBXA2R | |
| SCHEMBL3083812 | 0.76 | RPS6KA2 (0.43) | RPS6KA2RPS6KA3 | |
| SCHEMBL3081008 | 0.76 | SRD5A2 (0.38) | RPS6KA2RPS6KA3 | |
| SCHEMBL4144595 | 0.71 | RPS6KA3 (0.36) | RPS6KA2RPS6KA3SYKCYP11B2 | |
| SCHEMBL4144545 | 0.70 | RPS6KA2 (0.36) | RPS6KA2RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090136449-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136449-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | IDO1, IDO2, ZC3HAV1 | RPS6KA2 2578/4885RPS6KA3 1194/4885PADI4 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.